Revolution’s big reveal approaches
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
Merck also goes for all-comers in adjuvant lung
The Kandlelit-013 trial of calderasib plus Keytruda in adjuvant NSCLC will start in April.
CytomX emerges from masked obscurity
But now it must show that varseta-M can move into a registrational trial.
Takeda aims at Bristol and Merck
The Japanese group will soon start a trial of its Reblozyl rival in first-line MDS.
Spurned by Sanofi, Orano turns to Roche
The first fruit of a long-standing deal with Roche enters phase 1 in March.
BioNTech's patritumab me-too advances
The company's partner MediLink will start a pivotal trial of beruzatatug pelitecan in lung cancer.
Genmab taps ProfoundBio again
After several discontinuations, a new ADC enters the clinic.
The non-covalent BTK space expands
Hutchmed goes pivotal with HMPL-760 in B-cell lymphoma.
Another solstice for CTLA-4
Solstice Oncology acquires porustobart from Harbour Biomed.
Ideaya’s first pivotal catalyst looms
Darovasertib data are promised for the last week of March.
